Navigation Links
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
Date:7/15/2009

KENILWORTH, N.J., July 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. In this study, vicriviroc is being evaluated in a novel nucleoside-sparing regimen that is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment.

The study is being conducted in two stages, with the first stage initiated in January 2008 and having enrolled 95 patients (47-48 per treatment arm). Following 24 weeks of treatment, a formal interim analysis was conducted and the safety results were reviewed by an independent Data Safety Monitoring Board. Based on these results, the study has been extended to stage two, in which the enrollment target is an additional 105 patients.

Unlike other classes of HIV drugs that work to inhibit viral replication within human CD4+ cells, most of which are part of the immune system, vicriviroc is an HIV entry inhibitor designed to prevent the virus from infecting healthy CD4 cells by blocking its predominant entry route, the CCR5 co-receptor. Approximately 80-90 percent of treatment-naive patients have virus that uses the CCR5 co-receptor.(1)

"CCR5 antagonists, such as vicriviroc, have a novel mechanism of action and may play a unique role as physicians seek to construct new HIV regimens to meet the specific needs of their patients," said Joseph C. Gathe, Jr., M.D., F.A.C.P., clinical instructor, department of internal medicine, Baylor College of Medicine, Houston, and lead inve
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
2. Schering-Plough Announces Results of the Early ACS Trial
3. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
4. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
5. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
6. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
7. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
8. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
9. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
10. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the Morgan Stanley Global Healthcare ... , Presentation date: Tuesday September 9, 2014 , Presentation ... webcast and 30-day archive of this presentation will be available ... Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical company ...
(Date:9/2/2014)... , September 2, 2014 Today, ... (NYSE: WLP ), Tekmira Pharmaceuticals Corporation (NASDAQ: ... ZTS ), Sanofi SA (NYSE: SNY ) ... these notes ahead of publication. To reserve complementary membership, ... ,-- ,WellPoint Inc. Research Reports ,WellPoint Inc. (WellPoint) posted ...
(Date:9/2/2014)... DUBLIN , Sept. 2, 2014 Actavis ... the U.S. Food and Drug Administration (FDA) has accepted ... an investigational drug for the treatment of diarrhea and ... Irritable Bowel Syndrome (IBS-D).  Actavis, NDA for eluxadoline has ... Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO "The ...
Breaking Medicine Technology:Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4
... , SAN CLEMENTE, Calif., Nov. 17 Three ... ages of two through 12 are extremely, very, or ... according to a survey conducted by Opinion Research Corporation ... research of natural remedies including Sinupret® for Kids, a ...
... , DURHAM, N.C., Nov. 17 Oxygen Biotherapeutics, Inc. ... has begun shipping Dermacyte(TM) Oxygen Concentrate Gel to customers ... which are going out today, cover orders received through ... for our company - actually shipping a product to ...
Cached Medicine Technology:Survey Finds Mothers Take Children's Health Into Their Own Hands 2Survey Finds Mothers Take Children's Health Into Their Own Hands 3Survey Finds Mothers Take Children's Health Into Their Own Hands 4Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers 2
(Date:9/2/2014)... Breast cancer patients treated with lumpectomy followed by ... had bilateral mastectomy, according to a large study ... of Medicine and the Cancer Prevention Institute of ... California women with the disease is the first ... most common surgical interventions: bilateral mastectomy (the removal ...
(Date:9/2/2014)... Germany, September 2, 2014 In a large ... researchers found that mild cognitive impairment (MCI) occurred ... mellitus type 2. Interestingly, this strong association was ... in older participants (66-80 years) the association vanished. ... of Alzheimer,s Disease . , The concept of ...
(Date:9/2/2014)... the emergency department within a few days of discharge do ... have lost trust in other parts of the health care ... today in Annals of Emergency Medicine ( "Return ... , "When asked why they did not follow up ... too severe to wait until their scheduled appointment or being ...
(Date:9/2/2014)... The Dream2Walk Foundation along with Gas Monkey ... 2014 during Spinal Cord Injury Awareness Month featuring full band ... Chuck Ligon. Linear Automotive will be there hosting a Hot ... open at 2pm. The car show is Pre 1964 only, ... to the concert. There will be trophies for top 3 ...
(Date:9/2/2014)... Kathleen Doheny HealthDay ... The U.S. obesity epidemic is a driving force behind the ... study. Researchers looked at data from five national surveys ... increase in diabetes over time could be explained by factors ... U.S. adults. The investigators found that the prevalence of ...
Breaking Medicine News(10 mins):Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 2Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 4Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3
... As the U.S. immigrant population grows it will be necessary ... have access to health insurance coverage, or who face other ... (ACP) said in a new policy paper released today at ... and Access to Health Care discusses the challenges immigrants face ...
... , THURSDAY, April 7 (HealthDay News) -- After hooking up ... the computer to "read" the thoughts of disabled patients, thereby ... The researchers are hoping the breakthrough will one day lead ... world around them. "We have been fundamentally interested in ...
... NY) For many types of cancer, the original tumor ... a tiny subpopulation of cells from the primary tumor to ... too often kills the patient. Now, researchers at ... have identified two molecules that enable cancer to spread inside ...
... the American Thyroid Association (ATA) on outpatient radioiodine (131I) ... the safety of patients, their families, and the public. ... issue of Thyroid , a peer-reviewed journal published ... ATA recommendations are available free online at www.liebertpub.com/thy ...
... WEDNESDAY, April 6 (HealthDay News) -- Long-term users of the ... a new study. Brain scans showed an approximate 10 ... lower proportion of overall gray matter among long-term ecstasy users, ... who use ecstasy can develop serious memory problems, so a ...
... Virtual reality and other video games can significantly improve ... Michael,s Hospital. Patients who played video games, such ... likely to show improvements in arm motor function compared to ... is a promising and potentially useful alternative to enhance motor ...
Cached Medicine News:Health News:Physicians call for better access to health care for immigrants 2Health News:Physicians call for better access to health care for immigrants 3Health News:Scientists Use Computer to 'Read' Human Thoughts 2Health News:Scientists Use Computer to 'Read' Human Thoughts 3Health News:Molecules identified that help propel cancer metastasis 2Health News:New radiation treatment practice recommendations for thyroid disease 2Health News:Long-Term Ecstasy Users at Risk for Brain Damage, Study Warns 2Health News:Video games effective treatment for stroke patients: study 2
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... The WideBiter Punch series facilitates fast and ... a smooth, anatomically shaped meniscal rim. The ... profile to access even the tightest joint ... California, Inc., 20 years of engineering experience ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
... Punch series facilitates fast and effective resection ... anatomically shaped meniscal rim. The flat, crescent-shaped ... access even the tightest joint spaces. Made ... 20 years of engineering experience in arthroscopy ...
Medicine Products: